Primary central nervous system Hodgkin's lymphoma: a case report

被引:2
作者
Fu, Haiying [1 ]
Shi, Songsheng [2 ]
Chen, Lusan [3 ]
Xu, Benhua [4 ]
Huang, Wanling [1 ]
Chen, Yi [1 ]
Wu, Xuejing [3 ]
Shen, Jianzhen [1 ]
Liu, Tingbo [1 ]
机构
[1] Fujian Med Univ, Fujian Inst Haematol, Fujian Med Ctr Haematol, Dept Haematol,Fujian Prov Key Lab Haematol,Union, 29 Xinquan Rd, Fuzhou 350001, Fujian, Peoples R China
[2] Fujian Med Univ, Union Hosp, Dept Neurosurg, Fuzhou, Fujian, Peoples R China
[3] Fujian Med Univ, Union Hosp, Dept Pathol, Fuzhou, Fujian, Peoples R China
[4] Fujian Med Univ, Union Hosp, Dept Radiotherapy, Fuzhou, Fujian, Peoples R China
关键词
Primary central nervous system; Hodgkin' s lymphoma; programmed cell death-1; treatment; prognosis;
D O I
10.1177/0300060521999533
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Primary central nervous system Hodgkin's lymphoma (CNS-HL) is extremely rare. This current case report describes a 60-year-old male patient that presented with numbness of the left lower extremity and worsening headache. After a full range of investigations and a partial resection of the right cerebellum, external ventricular drainage reservoir placement and cranioplasty, he was diagnosed with primary CNS-HL. The patient was treated with 3 g/m(2) methotrexate (intravenous [i.v.], once a day, day 1) and 1 g/m(2) cytarabine (i.v., every 12 h, days 2 + 3), followed by anti-programmed cell death protein 1 antibodies (200 mg sintilimab, i.v., once a day, day 1, every 3 weeks). After six courses of treatment with intrathecal injections of 50 mg cytarabine (once a day, day 1) and 5 mg dexamethasone (once a day, day 1), there was no residual lesion on cranial magnetic resonance imaging. No significant drug-related adverse events were observed. The patient has been followed up every 3 months and no relapse has occurred.
引用
收藏
页数:8
相关论文
共 23 条
[1]   Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells [J].
Alvaro, T ;
Lejeune, M ;
Salvadó, MT ;
Bosch, R ;
García, JF ;
Jaén, J ;
Banham, AH ;
Roncador, G ;
Montalbán, C ;
Piris, MA .
CLINICAL CANCER RESEARCH, 2005, 11 (04) :1467-1473
[2]   Increased expression of CD4+CD25+FOXP3+ regulatory T cells correlates with Epstein-Barr virus and has no impact on survival in patients with classical Hodgkin lymphoma in Brazil [J].
Assis, Mariane C. G. ;
Campos, Antonio H. F. M. ;
Oliveira, Jose S. R. ;
Soares, Fernando A. ;
Silva, Joyce M. K. ;
Silva, Priscilla B. ;
Penna, Adriana D. ;
Souza, Eni M. ;
Baiocchi, Otavio C. G. .
MEDICAL ONCOLOGY, 2012, 29 (05) :3614-3619
[3]  
Biagi J, 2000, NEURO-ONCOLOGY, V2, P239, DOI 10.1093/neuonc/2.4.239
[4]  
Cecyn KZ, 2017, J Blood Lymph, V8, P196, DOI [10.4172/21657831.1000196, DOI 10.4172/21657831.1000196]
[5]  
Corti Marcelo, 2006, Braz J Infect Dis, V10, P403
[6]   Central nervous system involvement in Hodgkin's lymphoma [J].
Galan, L. ;
Sanchez, A. C. ;
Cantos, B. ;
Provencio, M. .
MEDICAL ONCOLOGY, 2011, 28 :S505-S508
[7]   CNS Hodgkin lymphoma [J].
Gerstner, Elizabeth R. ;
Abrey, Lauren E. ;
Schiff, David ;
Ferreri, Andres J. M. ;
Lister, Andrew ;
Montoto, Silvia ;
Tsang, Richard ;
Thiel, Eckhard ;
Graus, Francesc ;
Behringer, Dirk ;
Illerhaus, Gerald ;
Weaver, Susan ;
Wen, Patrick ;
Voloschin, Alfredo ;
Harris, Nancy Lee ;
Batchelor, Tracy T. .
BLOOD, 2008, 112 (05) :1658-1661
[8]   Unusual clinico-pathological features in primary Hodgkin's lymphomas of the central nervous system [J].
Gessi, Marco ;
Kuchelmeister, Klaus ;
Kellner, Udo ;
Ritter, Michael ;
Morgner, Anke ;
Urbach, Horst ;
Haenel, Mathias ;
Simon, Matthias ;
Pietsch, Torsten .
ACTA NEUROCHIRURGICA, 2013, 155 (01) :19-24
[9]  
Grimm Sean, 2011, Adv Hematol, V2011, P624578, DOI 10.1155/2011/624578
[10]  
Ha Tai-You, 2009, Immune Netw, V9, P209, DOI 10.4110/in.2009.9.6.209